Selected Publications
Publicatons at pitt
Gold, MS, Pineda-Farias JB, Close D, Patel S, Johnston PA, Stocker SD, Journigan VB. Subcutaneous administration of a novel TRPM8 antagonist reverses cold hypersensitivity while attenuating the drop in core body temperature. Br J Pharmacol. 2024 May 24. doi: 10.1111/bph.16429.
Ferrins L, Araujo E, Boudreau MW, Grenier-Davies MC, Haranahalli K, Journigan VB, Klug DM, Olson ME. Engaging the Medicinal Chemists of Tomorrow. J Med Chem. 2022 May 12;65(9):6353-6355.
Publications at MU
Cooper, S.Y., Akers, A.T., Journigan, V.B., Henderson, B.J. Novel Putative Positive Modulators of α4β2 nAChRs Potentiate Nicotine Reward-Related Behavior. Molecules. 2021 Aug 7;26(16):4793. doi: 10.3390/molecules26164793. PMID: 34443380 PMCID: PMC8398432
Journigan, V.B.*, Alarcón-Alarcón, D., Feng, Z., Wang, Y., Liang, T., Dawley, D., Amin, A.R.M.R., Montano, C., Van Horn, W.D., Xie, X.-Q., Ferrer-Montiel, A., Fernández-Carvajal, A. Structural and in vitro functional characterization of a menthyl TRPM8 antagonist indicates species-dependent regulation. ACS Med Chem Lett. 2021 Mar 31;12(5):758-767. doi: 10.1021/acsmedchemlett.1c00001. PMID: 34055223 PMCID: PMC8155240 *corresponding author.
Journigan VB*, Feng Z, Rahman S, Wang Y, Amin ARMR, Heffner CE, Bachtel N, Wang S, Gonzalez-Rodriguez S, Fernández-Carvajal A, Fernández-Ballester G, Hilton JK, Van Horn WD, Ferrer-Montiel A, Xie X-Q, Rahman T. Structure-based design of novel biphenyl amide antagonists of human Transient Receptor Potential Cation Channel Subfamily M Member 8 channels (TRPM8) with potential implications in the treatment of sensory neuropathies. ACS Chem. Neurosci. 2020, 11, 268-290. PMID: 31850745, PMCID: PMC7153518. *corresponding author
Journigan VB. Marshall University Research Corporation, assignee. Transient Receptor Potential Melastatin 8 (TRPM8) antagonists and related methods. WO 2020160464 A1.
Publications prior to MU
Mottinelli M, Journigan VB, Obeng S, Pallares VLC, Mѐsangeau C, Kapanda CN, Cutler SJ, Lambert JA, Eans SO, Ganno ML, Sheng W, King T, Sharma A, Mollereau C, Avery BA, McLaughlin JP, McCurdy CR. Dual Opioid-Neuropeptide FF Small Molecule Ligands Demonstrate Analgesia with Reduced Tolerance Liabilities. Proc Natl Acad Sci U S A., submitted. equal author contribution.
Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisanò CA, Morella I, Fasano S, Journigan BV, Meyer ME, Polgar WE, Brambilla R, Zaveri NT, Morari M. Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists. Br J Pharmacol. 2018 Mar;175(5):782-796. doi: 10.1111/bph.14123. Epub 2018 Jan 31. PubMed PMID: 29232769; PubMed Central PMCID: PMC5811622.
Kallupi M, Shen Q, de Guglielmo G, Yasuda D, Journigan VB, Zaveri NT, Ciccocioppo R. Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption. Addict Biol. 2018 Mar;23(2):585-595. doi: 10.1111/adb.12513. Epub 2017 Jun 21. PubMed PMID: 28635181; PubMed Central PMCID: PMC5740020.
Journigan VB, Polgar WE, Tuan EW, Lu J, Daga PR, Zaveri NT. Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships. Sci Rep. 2017 Oct 16;7(1):13255. doi: 10.1038/s41598-017-13129-1. PubMed PMID: 29038479; PubMed Central PMCID: PMC5643385.
Ferrari F, Malfacini D, Journigan BV, Bird MF, Trapella C, Guerrini R, Lambert DG, Calo' G, Zaveri NT. In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403. Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.333. PubMed PMID: 28805972; PubMed Central PMCID: PMC5684865.
Zaveri NT, Meyer M, Journigan VB, Yasuda D; Astraea Therapeutics, LLC, assignee.Preparation of piperidinyl-containing nociceptin receptor ligand compounds. WO 2017096323; US20180155314 A1
Ferrari F, Cerlesi MC, Malfacini D, Asth L, Gavioli EC, Journigan BV, Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Rizzi A, Guerrini R, Ruzza C, Zaveri NT, Calo G. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. Eur J Pharmacol. 2016 Dec 15;793:1-13. doi: 10.1016/j.ejphar.2016.10.025. Epub 2016 Oct 22. PubMed PMID: 27780725; PubMed Central PMCID: PMC5555400.
Zaveri NT, Journigan VB, Polgar WE. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors. ACS Chem Neurosci. 2015 Apr 15;6(4):646-57. doi: 10.1021/cn500367b. Epub 2015 Feb 18. PubMed PMID: 25635572; PubMed Central PMCID: PMC4401318.
Journigan VB, Mésangeau C, Vyas N, Eans SO, Cutler SJ, McLaughlin JP, Mollereau C, McCurdy CR. Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors. J Med Chem. 2014 Nov 13;57(21):8903-27. doi: 10.1021/jm500989n. Epub 2014 Oct 21. PubMed PMID: 25268943; PubMed Central PMCID: PMC4234442.
Journigan VB, Polgar WE, Khroyan TV, Zaveri NT. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II. Bioorg Med Chem. 2014 Apr 15;22(8):2508-16. doi: 10.1016/j.bmc.2014.02.047. Epub 2014 Mar 5. PubMed PMID: 24657054; PubMed Central PMCID: PMC4033624.
Journigan VB, Zaveri NT. TRPM8 ion channel ligands for new therapeutic applications and as probes to study menthol pharmacology. Life Sci. 2013 Mar 19;92(8-9):425-37. doi: 10.1016/j.lfs.2012.10.032. Epub 2012 Nov 16. Review. PubMed PMID: 23159643.
Zaveri NT, Yasuda D, Journigan BV, Daga PR, Jiang F, Olsen C. Structure-Activity Relationships of Nociceptin Receptor (NOP) Ligands and the Design of Bifunctional NOP/Mu Opioid Receptor-Targeted Ligands . In: ACS Symposium Series. Washington, DC: American Chemical Society; 2013. Chapter 8; p.145–160.
Gregory SM, Cavenaugh A, Journigan V, Pokorny A, Almeida PF. A quantitative model for the all-or-none permeabilization of phospholipid vesicles by the antimicrobial peptide cecropin A. Biophys J. 2008 Mar 1;94(5):1667-80. doi: 10.1529/biophysj.107.118760. Epub 2007 Oct 5. PubMed PMID: 17921201; PubMed Central PMCID: PMC2242756.